Alzamend Neuro Reveals Promising Pharmacodynamic Data from Phase II Trial of AL001 for Brain Disorders Alzamend Neuro's Phase II trial results reveal promising insights about AL001's unique neurochemical effects, suggesting better tolerance than lithium carbonate.

Alzamend Neuro Reveals Promising Pharmacodynamic Data from Phase II Trial of AL001 for Brain Disorders #United_States #Boston #Lithium #Alzamend_Neuro #AL001

Alzamend Neuro Launches Phase II Study for AL001 in Bipolar Disorder with Major Boston Hospital Alzamend Neuro has commenced a Phase II trial of its innovative lithium-based treatment, AL001, for bipolar disorder patients, collaborating with Massachusetts General Hospital.

Alzamend Neuro Launches Phase II Study for AL001 in Bipolar Disorder with Major Boston Hospital #United_States #Boston #Bipolar_Disorder #Alzamend_Neuro #AL001

Alzamend Neuro Completes Phase II Clinical Trial of AL001 to Transform Lithium Therapy Alzamend Neuro has finalized the clinical segment of its Phase II trial for AL001, aiming to revolutionize lithium treatment for mental health disorders. Topline data expected in early 2026.

Alzamend Neuro Completes Phase II Clinical Trial of AL001 to Transform Lithium Therapy #United_States #Atlanta #Alzamend_Neuro #AL001 #Lithium_Therapy